James Colin R, Quinn Jennifer E, Mullan Paul B, Johnston Patrick G, Harkin D Paul
Centre for Cancer Research and Cell Biology, Queen's University Belfast, University Floor, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, UK.
Oncologist. 2007 Feb;12(2):142-50. doi: 10.1634/theoncologist.12-2-142.
To date, estrogen receptor, progestogen receptor, and HER2/neu represent molecular biomarkers currently used in routine clinical practice to aid treatment decisions. Over the last few years, a large body of preclinical and retrospective clinical data has accumulated that suggests that BRCA1 mutation functions as a novel predictive marker of response to chemotherapy. This article reviews the role of BRCA1 as a predictive marker of chemotherapy response in breast cancer and examines the link between BRCA1 deficiency and the basal-like phenotype. Search strategy. Data for this article were identified through MEDLINE and PubMed searches for published reports using the terms BRCA1, breast cancer, basal-like, chemotherapy, prognosis, and predictive markers. In some cases, due to the restriction of space, readers are referred to review articles to allow further reading. Only articles published in English were included.
迄今为止，雌激素受体、孕激素受体和HER2/neu是目前常规临床实践中用于辅助治疗决策的分子生物标志物。在过去几年中，积累了大量临床前和回顾性临床数据，表明BRCA1突变是化疗反应的一种新型预测标志物。本文综述了BRCA1作为乳腺癌化疗反应预测标志物的作用，并探讨了BRCA1缺陷与基底样表型之间的联系。检索策略。本文的数据通过MEDLINE和PubMed检索已发表的报告确定，检索词为BRCA1、乳腺癌、基底样、化疗、预后和预测标志物。在某些情况下，由于篇幅限制，建议读者查阅综述文章以便进一步阅读。仅纳入以英文发表的文章。
